Neuropace conducted a randomized trial involving 191 patients over a period of three-months after which it found that the device was able to cut down the number of seizures by 38 percent per month.
"The neurostimulator detects abnormal electrical activity in the brain and responds by delivering electrical stimulation intended to normalize brain activity before the patient experiences seizure symptoms", the director of the Office of Device Evaluation in the FDA's Center for Devices and Radiological Health, Christy Foreman said.
Source: Medindia
